Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Alzheon announced it raised $78.8 Million in an initial filing from an offering of $500 Million
PRIVATESep 10, 2026•about 2 hours ago
Amount Raised
$78.8 Million
Round Type
Venture - Series Unknown
FraminghamBiotechnology
Company Information
Company
Alzheon
Location
111 Speen Street
Framingham, Massachusetts, United States
About
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.
Don't miss Alzheon's next move
Get an email the moment Alzheon raises, hires an exec, or expands, usually minutes after it happens.
FraminghamBiotechnology